Gene · 5558
PRIM2: DNA primase subunit 2
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. PRIM2: DNA primase subunit 2. Genes, record 5558. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/5558
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P49643 | DNA primase large subunit | 509 | 22 | Ensembl, GeneID, HGNC |
Source UniProt
Patents20
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4650780 A2 | 2025-11-19 | 18834 | P49643 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 23508 | P49643 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 23508 | P49643 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 18834 | P49643 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 66623 | P49643 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 169594 | P49643 | Espacenet |
| US 8703930 B2 | 2014-04-22 | 658 | P49643 | Espacenet |
| US 8586006 B2 | 2013-11-19 | 22456 | P49643 | Espacenet |
| US 8470798 B2 | 2013-06-25 | 658 | P49643 | Espacenet |
| EP 2520652 A2 | 2012-11-07 | 658 | P49643 | Espacenet |
1 to 10 of 20
See all 20 patentsDrugs7
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ASPACYTARABINE | CHEMBL4297599 | DNA polymerase (alpha/delta/epsilon) inhibitor | INHIBITOR | ChEMBL |
| CLOFARABINE | CHEMBL1750 | DNA polymerase (alpha/delta/epsilon) inhibitor | INHIBITOR | ChEMBL |
| CYTARABINE | CHEMBL803 | DNA polymerase (alpha/delta/epsilon) inhibitor | INHIBITOR | ChEMBL |
| FLUDARABINE PHOSPHATE | CHEMBL1096882 | DNA polymerase (alpha/delta/epsilon) inhibitor | INHIBITOR | ChEMBL |
| GEMCITABINE | CHEMBL888 | DNA polymerase (alpha/delta/epsilon) inhibitor | INHIBITOR | ChEMBL |
| GEMCITABINE HYDROCHLORIDE | CHEMBL1637 | DNA polymerase (alpha/delta/epsilon) inhibitor | INHIBITOR | ChEMBL |
| TROXACITABINE | CHEMBL359164 | DNA polymerase (alpha/delta/epsilon) inhibitor | INHIBITOR | ChEMBL |
Trials4,186
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07604766 | GEMCITABINE | PHASE3 | ClinicalTrials.gov | |
| NCT07604233 | CYTARABINE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07603557 | FLUDARABINE PHOSPHATE | PHASE2 | ClinicalTrials.gov | |
| NCT07602140 | GEMCITABINE | PHASE2 | ClinicalTrials.gov | |
| NCT07598318 | GEMCITABINE | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT07588360 | CYTARABINE | ClinicalTrials.gov | ||
| NCT07583888 | CYTARABINE | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT07579195 | GEMCITABINE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07575191 | GEMCITABINE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07570849 | GEMCITABINE | PHASE2 | ClinicalTrials.gov |
1 to 10 of 4,186
See all 4,186 trialsNIH grants690
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | PRIM2 papers | Newest fiscal year |
|---|---|---|---|
| P30CA036727 | Buffett Cancer Center Support Grant | 8 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 5 | 2025 |
| R35GM118089 | Integrative Structural Biology in DNA Replication and Damage Response | 5 | 2025 |
| U19AI135972 | SARS-CoV adaptations through a Systems Biology Lens (SYBIL) | 5 | 2025 |
| P30CA015083 | Mayo Clinic Comprehensive Cancer Center Support Grant | 3 | 2025 |
| P30CA015704 | Cancer Center Support Grant | 3 | 2025 |
| P30CA068485 | Cancer Center Support Grant | 3 | 2025 |
| R01HG002385 | Long-read sequence and assembly of segmental duplications | 3 | 2025 |
| U19AI135990 | HPMI: Host Pathogen Mapping Initiative | 3 | 2025 |
| P01AI063302 | The intersection of innate and adaptive immunity to intracellular pathogens | 2 | 2025 |
1 to 10 of 690Source NIH's project files
See all 690 nih grantsPapers465
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Primase subunit 2 regulates the proliferation and apoptosis of gastric cancer cells via MCM7/CDK4 and Bax/Bcl-2 pathways. | Biochim Biophys Acta Gen Subj | 2026 | 41967775 | PubTator, text mining | PubMed |
| LARS promotes osteosarcoma proliferation through leucine-dependent PRIM2 translation and DNA replication activation. | J Exp Clin Cancer Res | 2026 | 41832550 | PubTator, text mining | PubMed |
| (±)-2-Cyclohexyl-5-methoxy-2H-chromene, a Synthetic 5-Methoxyflavone Derivative, Is a Selective DNA Polymerase-β Inhibitor with Neuroprotective Activity against β-Amyloid Toxicity. | ACS Chem Neurosci | 2026 | 41367307 | PubTator, text mining | PubMed |
| Identifying sepsis susceptibility genes in post-surgical patients using an artificial intelligence approach. | Front Med (Lausanne) | 2025 | 41473159 | PubTator, text mining | PubMed |
| Piwil-2 represents a poor prognosticator in Merkel cell carcinomas that regulates oncoproteins, cell cycle arrest and SOX-2 expression. | Sci Rep | 2025 | 41213968 | PubTator, text mining | PubMed |
| Signaling pathway of DNA replication and toll-like receptors was inhibited in C6/36 cells infected with Japanese encephalitis virus. | Virol J | 2025 | 41188955 | PubTator, text mining | PubMed |
| Requirements for establishment and epigenetic stability of mammalian heterochromatin. | Mol Cell | 2025 | 40972525 | PubTator, text mining | PubMed |
| DNA polymerase α/primase extraction from chromatin by VCP/p97 restricts ATR activation during unperturbed DNA replication. | Nat Commun | 2025 | 40593507 | PubTator, text mining | PubMed |
| Single-cell RNA sequencing of the holothurian regenerating intestine reveals the pluripotency of the coelomic epithelium. | Elife | 2025 | 40111904 | PubTator, text mining | PubMed |
| Genome-Wide Association Study of Temporomandibular Disorder-Related Pain in Finnish Populations. | J Oral Rehabil | 2025 | 39482899 | PubTator, text mining | PubMed |
1 to 10 of 465
See all 465 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/5558
GET https://conductscience.org/api/genes/v1/5558/patents